While the biotech world chases cancer cures, Synvect is quietly building a weapon against humanity's deadliest animal: the mosquito. They aren't just swatting them—they're rewriting their DNA.

"Synvect isn't selling a product; they're selling a biological inevitability. Once the gene drive is set, the mosquitoes self-terminate."

The website traffic is minimal (278 monthly visits), but that's deceptive for a B2B deep tech play. Their audience isn't the general public; it's government health agencies, NGOs, and agricultural conglomerates. The 'undefined' country traffic suggests either a stealth launch or a global testing phase where location data is anonymized.

• Nikolay Kandul & Pooja Patel are the scientific visionaries behind the tech stack.
• Their tech stack (Tailwind, jQuery) suggests a rapid MVP deployment rather than a polished consumer product—prioritizing function over form.
• The 'Early Access' page is the primary funnel, indicating they are likely in the pilot phase of client acquisition.